



BUSINESS & FINANCIAL UPDATE 1Q20



MAY 7, 2020

Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma S.A., including estimates of target market opportunity, timing of planned clinical trials and results from those trials, regulatory strategy and timing of planned regulatory submissions, manufacturing capabilities and strategy for expansion of the ERYCAPS platform. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimates based upon the information available to ERYTECH Pharma S.A. as of the date of this presentation. The company's expectations regarding the effects of COVID-19 on the Company's trials and development may be incorrect. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements. Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statement.

Business & Financial Update Q1 2020

AGENDA

	Business Update	
	Financial Highlights Q1 2020	
	News Flow and Milestones	
	Q & A Session	

Leader in Red Blood Cell-based Cancer Therapeutics



Reproducible encapsulation of therapeutic compounds in red blood cells



Focus on oncology, targeting cancer cells' altered amino acid metabolism through encapsulated asparaginase



Lead product candidate eryaspase, first asparaginase to show efficacy in solid tumors; strongest survival benefit observed in any 2L pancreatic cancer study to date




Phase 3 trial in 2L pancreatic cancer ongoing in EU and US; Phase 2 in 1L TNBC and Phase 2 IST in 2L ALL ongoing



Industrialized production: own cGMP production facilities in the United States and Europe



Listed on Nasdaq and Euronext; cash runway into Q1 2021



Hammel et al., European Journal of Cancer, 2019

Business Highlights – TRYbeCA-1



TRYbeCA 1, Phase 3 trial of eryaspase in second-line (2L) pancreatic cancer (N ≈ 500)

- More than 75% of approximately 500 patients enrolled
- Third positive safety review by independent data monitoring committee, now on 320 patients
- Fast-Track designation granted by the FDA
- Impact of COVID-19 pandemic well managed
 - Successfully implemented measures to preserve study integrity
 - Anticipated delay in enrollment limited to 3-4 months; full enrollment expected Q4 2020
- Number of total events lower than expected projections
- Interim superiority analysis expected around year-end 2020
 - Two possible outcomes:
 - (a) stop if primary survival endpoint already met or
 - (b) continue study as planned
 - If (b), final analysis expected in 2H 2021

Business Highlights – Other eryaspase Trials

Phase 2 proof of concept trial ongoing in triple-negative breast cancer (TNBC) in Europe (N ≈ 64)

- 17 sites activated in three countries; enrolling patients
- Results expected in 2021



Phase 1 IST in 1L pancreatic cancer in combination with FOLFIRINOX in preparation (N=12-18)

- Sponsored by Georgetown University; obtained IND clearance from US FDA
- Trial expected to start patient enrollment in 2H20


Phase 2 IST in 2L ALL in Nordic countries of Europe nearing complete enrollment (N=50)

- Interim update expected in 1H20, full results by EOY

Business Highlights – EU Horizon 2020 - EVIDENCE Consortium

ERYTECH part of RBC research consortium in EU Horizon 2020 program

- Consortium will explore how red blood cells are influenced by their extra-cellular environment
- Led by Professor Lars Kaestner of Saarland University in Germany
- Other members include international blood experts and key opinion leaders from:
 - CNRS, France
 - INSERM, France
 - University of Zurich, Switzerland
 - University of Bristol, Great Britain
 - Sanquin Research, Netherlands
 - Nanion, Germany
 - R&R Mechatronics, Netherlands
 - CTC Research, Germany
 - University of Grenoble (CNRS), France
 - Vall d'Hebron University Hospital, Barcelona, Spain
 - The Institute for Bioengineering of Catalonia, Barcelona, Spain



EVIDENCE

Financial Highlights

- As of March 31, 2020, cash and cash equivalents totaling €58.6 million (approximately \$64.6 million),
 - Compared with €73.2 million on December 31, 2019.
 - The €14.6 million decrease in cash position in the first quarter 2020 was the result of:
 - €16.7 million net cash utilization in operating activities, inline with operating plan;
 - €1.1 million used for investing activities;
 - €2.4 million generated in financing activities
 - €0.7 million favorable currency exchange impact of the U.S. dollar against the euro
- While closely monitoring the budget impact of the COVID-19 pandemic on its operations, the Company confirms its previous guidance on sufficient cash position to fund operations into Q1 2021.
- Due to COVID-related challenges to compile full financial information and organize auditors review, the P&L details for the first quarter 2020 will be provided at a later time.

Key Milestones Anticipated over Next 12 Months

- ❑ Interim update on Phase 2 IST in 2L acute lymphoblastic leukemia (ALL)
- ❑ Initiation of Phase 1 IST with eryaspase in 1L pancreatic cancer
- ❑ **Interim (superiority) analysis in TRYbeCA-1**
- ❑ Full results of Phase 2 IST in 2L ALL

Thank you! Questions?



ERYTECH Pharma SA
60 Avenue Rockefeller
69008 Lyon
France



ERYTECH Pharma Inc
1 Main Street
Cambridge, MA 02142
USA

www.erytech.com